Long-Term Changes of Urinary Exosomal Peptide Levels After Thyroidectomy in Patients with Thyroid Cancer: A Prospective Observational Study
Chih-Yuan Wang,Shyang-Rong Shih,Kuen-Yuan Chen,Yi-Chieh Chung,Pei-Jie Huang
DOI: https://doi.org/10.2147/ijn.s458931
IF: 7.033
2024-05-23
International Journal of Nanomedicine
Abstract:Chih-Yuan Wang, 1 Shyang-Rong Shih, 1 Kuen-Yuan Chen, 2 Yi-Chieh Chung, 1 Pei-Jie Huang 1 1 Department of Internal Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan; 2 Department of Internal Surgery, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan Correspondence: Chih-Yuan Wang, Department of Internal Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, 7, Chung-Shan South Road, Taipei, Taiwan, Email ; Background: The recurrence rate of thyroid cancer can be as high as 30%. The purpose of this study was to examine changes of urine exosomal peptide levels after thyroidectomy in patients with thyroid cancer to determine if levels can predict the risk of recurrence. Methods: Patients > 20 years old as newly diagnosed with papillary thyroid cancer who had received a thyroidectomy were recruited. Urine samples were collected at 12 months after enrollment to the study, and 1 year later. Urine exosomes containing different peptides were identified and compared. Results: A total of 70 patients were enrolled in the study, and were classified by the interval between surgery and enrollment: 42 patients with < 5 years between surgery and enrollment, 14 patients between 5– 10 years, and 14 patients longer than 10 years. No recurrence was observed in any patient during the 2 years after enrollment. No significant differences were found in the levels of serum proteins or urine exosomal peptides between groups, or between intervals. Known risk factors for high-risk thyroid cancer had only a mild correlation with serum protein levels and urine exosomal peptides. Conclusion: Our study revealed the long-term basal fluctuation ranges of serum proteins and urine exosomal peptides in patients with thyroid cancer who underwent thyroidectomy. For high-risk patients after thyroidectomy, concentrations of serum proteins or urine exosomal peptides within the ranges may indicate there is a lower risk of thyroid cancer recurrence during long-term follow-up. Trial Registration: ClinicalTrials.gov: NCT03488134. Keywords: thyroid cancer, urine exosome, peptide, thyroglobulin, recurrence Thyroid cancer is not uncommon, and annually there are about 53,000 new cases of thyroid cancer in the United States (US). 1–3 The disease affects both women and men, and is commonly diagnosed in the fourth through sixth decades of life. 1–3 The most common pattern of thyroid cancer is papillary, which accounts for about 80% of patients and it responds well to treatment and is rarely fatal. 1–3 Follicular thyroid cancer accounts for about 15% of cases, and metastasis to bones and lungs is common. 1–3 Medullary and anaplastic thyroid cancers each account for about 2% of cases, and are aggressive diseases. 1–3 Surgery and radioiodine are the most common treatment for thyroid cancer, and radiation therapy and chemotherapy may be used for advanced disease. 1–3 Despite advances in understanding the pathogenesis of thyroid cancer and novel treatments, the recurrence rate of thyroid cancer after thyroidectomy ranges from 10% to 28%. 4,5 Risk factors for recurrence of thyroid cancer after thyroidectomy include male sex, tumor diameter, lymph node metastasis, and pathological type. 4 While monitoring serum thyroglobulin levels is recommended to identify recurrence after thyroidectomy, 6 however, several studies and meta-analysis have shown that serum thyroglobulin level is not useful for predicting recurrence of thyroid cancer with lobectomy. 7–10 As such, the development of non-invasive and more sensitive biomarkers for early detection of recurrence is crucial for the lifelong follow-up required by all these patients. Exosomes are micro-vesicles with a diameter of around 100 nm formed by endocytosis that are produced by most if not all cells types, and are excreted into the extracellular matrix or body fluids including serum, urine, saliva, sweat and ascites. 11–13 Exosomes can carry nucleic acids, proteins, and lipids that are unique to the origin cell. 11–13 Since the contents of exosomes are based on the donor cell, studies are revealing that they hold promise for the diagnosis of diseases and malignancies. 13–16 A number of studies have indicated that exosomes hold promise in the diagnosis and management of thyroid diseases, including malignancy. 17–19 Our previous study found that urine exosomal thyroglobulin level revealed statistically significant higher in patients with thyroid cance -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology